GABAA receptors as targets for novel anxiolytic drugs

World Journal of Biological Psychiatry

Volumn 7, Issue 4, 2006, Pages 231-237

  Rupprecht, Rainer ^a   Eser, Daniela ^a   Zwanzger, Peter ^a   Möller, Hans Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Anxiety disorders; Anxiolytics; Benzodiazepines; GABAA receptor; Neuroactive steroids

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; DIAZEPAM; ELB 139; GABOXADOL; NEUROACTIVE STEROID; OCINAPLON; PLACEBO; PREGABALIN; SL 651498; STEROID; TIAGABINE; TP 003; TPA 023; UNCLASSIFIED DRUG; VIGABATRIN; ANXIOLYTIC AGENT;

ANXIETY DISORDER; CLINICAL TRIAL; DISABILITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TARGETING; HUMAN; LIVER TOXICITY; LONG TERM CARE; NONHUMAN; PREVALENCE; PSYCHOPHARMACOTHERAPY; REVIEW; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VISUAL FIELD DEFECT; ANIMAL; CHEMISTRY; DRUG EFFECT; MOUSE;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; HUMANS; MICE; RECEPTORS, GABA-A;

EID: 33750475904     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970600868525     Document Type: Review

References (59)

1. Atack, JR and Wafford, KA and Tye, SJ and Cook, SM and Sohal, B and Pike, A and Sur, C and Melillo, D and Bristow, L and Bromidge, F and Ragan, I and Kerby, J and Street, L and Carling, R and Castro, JL and Whiting, P and Dawson, GR and McKernan, RM. (2006) TPA023
2. Baldwin, DS and Polkinghorn, C. (2004) Evidence-based pharmacotherapy of generalized anxiety disorder Int J Neuropsychopharmacol, 8, pp. 1-10.
3. Baldwin, DS and Anderson, IM and Nutt, DJ and Bandelow, B and Bond, A and Davidson, JR and den Boer, JA and Fineberg, NA and Knapp, M and Scott, J and Wittchen, HU. (2005) evidence-based guidelines for the pharmacological treatment of anxiety disordrs: Recommendations from the British Association for Psychopharmacology J Psychopharmacol, 19, pp. 567-596.
4. Ballenger, JC and Burrows, GD and DuPont, RL, Jr and Lesser, IM and Noyes, R, Jr and Pecknold, JC and Rifkin, A and Swinson, RP. (1988) Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. I. Efficacy in short-term treatment Arch Gen Psychiatry, 45, pp. 413-422.
5. Bandelow, B and Zohar, J and Hollander, E and Kasper, S and Möller, H-J. (2002) Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic disorders World J Biol Psychiatry, 3, pp. 171-199.
6. A receptor Nat Neurosci, 6, pp. 565-575.
7. Carling, RW and Madin, A and Guiblin, A and Russell, MG and Moore, KW and Mitchinson, A and Sohal, B and Pike, A and Cool, SM and Ragan, IC and McKernan, RM and Quirk, K and Ferris, P and Marshall, G and Thompson, SA and Wafford, KA and Dawson, GR and Atack, JR and Harrison, T and Castro, JL and Street, LJ. (2005)
8. Carpenter, LL and Schecter, JM and Tyrka, AR and Mello, MF and Haggarty, R and Price, LH. (2006) Open-label tiagabine monotherapy for major depressive disorder with anxiety J Clin Psychiatry, 67, pp. 66-71.
9. Connor, KM and Davidson, JR and Weisler, RH and Zhang, W and Abraham, K. (2006) Tiagabine for posttraumaic stress disorder: Effects of open-label and double-blind discontinuation treatment Psychopharmacology, 184, pp. 21-25.
10. A-receptor clustering results in enhanced anxiety and a bias for threat cues Nat Neurosci, 9, pp. 833-839.
11. Crestani, F and Low, K and Keist, R and Mandelli, M and Mohler, H and Rudolph, U. (2001) Molecular targets for the myorelaxant action of diazepam Mol Pharmacol, 59, pp. 422-445.
12. Crestani, F and Keist, R and Fritschy, JM and Benke, D and Vogt, K and Prut, L and Bluthmann, H and Mohler, H and Rudolph, U. (2002) Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors Proc Natl Acad Sci USA, 99, pp. 8980-8985.
13. Daneshvar, H and Racette, L and Coupland, SG and Kertes, PJ and Guberman, A and Zackon, D. (1999) Symptomatic and asymptomatic visual loss in patients taking vigabatrin Ophthalmology, 106, pp. 1792-1798.
14. A modulators CNS Spectrums, 10, pp. 21-27.
15. A receptors in mediating the anxiolytic effects of benzodiazepines J Neurosci, 25, pp. 10682-10688.
16. Eke, T and Talbot, JF and Lawden, MC. (1997) Severe persistent visual field constriction associated with vigabatrin Br Med J, 314, pp. 180-181.
17. A agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans Psychopharmcology, 130, pp. 285-291.
18. Feltner, DE and Crockatt, JG and Dubovsky, SJ and Cohn, CK and Shrivastava, RK and Targum, SD and Liu-Dumaw, M and Carter, CM and Pande, AC. (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder J Clin Psychopharmacol, 23, pp. 240-249.
19. Goodacre, SC and Street, LJ and Hallett, DJ and Crawforth, JM and Kelly, S and Owens, AP and Blackaby, WP and Lewis, RT and Stanley, J and Smith, AJ and Ferris, P and Sohal, B and Cook, SM and Pike, A and Brown, N and Wafford, KA and Marshall, G and Castro, JL and Atack, JR. (2006) Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders J Med Chem, 49, pp. 35-38.
20. A receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms CNS Drug Rev, 9, pp. 3-20.
21. Gulinello, M and Gong, QH and Smith, SS. (2003) Progesterone withdrawal increases the anxiolytic actions of gaboxadol: Role of alpha4betadelta GABA(A) receptors Neuroreport, 14, pp. 43-46.
22. Hoehn-Saric, R. (1983) Effects of THIP on chronic anxiety Psychophopharmacology, 80, pp. 338-341.
23. Kessler, RC and Chiu, WT and Jin, R and Ruscio, AM and Shear, K and Walters, EE. (2006) The epidemiology of panic attacks, panic disorder, and agoraphobia in the national comorbidity survey replication Arch Gen Psychiatry, 63, pp. 415-424.
24. Kita, A and Kohayakawa, H and Kinoshita, T and Ochi, Y and Nakamichi, K and Kurumiya, S and Furukawa, K and Oka, M. (2004) Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand Br J Pharmacol, 142, pp. 1059-1072.
25. A agonist THIP (gaboxadol) increases non-REM sleep and enhances delta activity in the rat Neuroreport, 7, pp. 2241-2245.
26. A receptor J Pharmacol Exp Ther, 314, pp. 717-724.
27. A receptor modulator Proc Natl Acad Sci USA, 102, pp. 7380-7385.
28. Löw, K and Crestani, F and Keist, R and Benke, D and Brünig, I and Benson, JA and Fritschy, J-M and Rülicke, T and Bluethmann, H and Möhler, H and Rudolph, U. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety Science, 290, pp. 131-134.
29. McKernan, RM and Rosahl, TW and Reynolds, DS and Sur, C and Wafford, KA and Atack, JR and Farrar, S and Myers, J and Cook, G and Ferris, P and Gerrett, L and Bristow, L and Marshall, G and Macaulay, A and Brown, N and Howell, O and Moore, KW and Carling, RW and Street, LJ and Castro, JL and Ragan, CI and Dawson, GR and Whiting, PJ. (2000) Nat Neurosci, 3, pp. 587-592.
30. A -receptor subtypes: A new pharmacology Curr Opin Pharmacol, 1, pp. 22-25.
31. Möhler, H and Fritschy, J-M and Rudolph, U. (2002) A new benzodiazepine pharmacology J Pharmacol Exp Ther, 300, pp. 2-8.
32. A-benzodiazepine receptor in psychiatric disorder Br J Psychiatry, 179, pp. 390-396.
33. Nutt, DJ and Ballenger, JC and Sheehan, D and Wittchen, HU. (2002) Generalized anxiety disorder: Comorbidity, comparative biology and treatment Int J Neuropsychopharmacol, 5, pp. 315-325.
34. Pande, AC and Feltner, DE and Jefferson, JW and Davidson, JRT and Pollack, M and Stein, MB and Lydiard, RB and Futterer, R and Robinson, P and Slomkowski, M and DuBoff, E and Phelps, M and Janney, CA and Werth, JL. (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder J Clin Psychopharmacol, 24, pp. 141-149.
35. Papadopoulos, V and Lecanu, L and Brown, RC and Han, Z and Yao, ZX. (2005) Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders Neuroscience, 138, pp. 749-756.
36. Paul, SM and Purdy, RH. (1992) Neuroactive steroids FASEB J, 6, pp. 2311-2322.
37. Pohl, RB and Feltner, DE and Fieve, RR and Pande, AC. (2005) Efficacy of pregabalin in the treatment of generalized anxiety disorder J Clin Psychopharmacol, 25, pp. 151-158.
38. Pollack, MH and Roy-Byrne, PP and Van Ameringen, M and Snyder, H and Brown, C and Ondrasik, J and Rickels, K. (2005) The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: Results of a placebo-controlled study J Clin Psychiatry, 66, pp. 1401-1408.
39. A receptors Neuron, 4, pp. 759-765.
40. Rickels, K and Pollack, MH and Feltner, DE and Lydiard, RB and Zimbroff, DL and Bielski, RJ and Tobias, K and Brock, JD and Zornberg, GL and Pande, AC. (2005) Pregabalin for treatment of generalized anxiety disorder: A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam Arch Gen Psychiatry, 62, pp. 1022-1030.
41. Rosenthal, M. (2003) Tiagabine for the treatment of generalized anxiety disorder: A randomized, open-label, clinical trial with paroxetine as a positive control J Clin Psychiatry, 64, pp. 1245-1249.
42. A receptor subtypes Nature, 401, pp. 796-797.
43. A receptor subtypes: Dissecting their pharmacological functions Trends Pharmacol Sci, 22, pp. 188-194.
44. Rupprecht, R. (2003) Neuroactive steroids: Mechanisms of action and neuropsychopharmacological properties Psychoneuroendocrinology, 28, pp. 139-168.
45. Rupprecht, R and Holsboer, F. (1999) Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives Trends Neurosci, 22, pp. 410-416.
46. Russell, MG and Carling, RW and Street, LJ and Hallet, DJ and Goodacre, S and Mezzogori, E and Reader, M and Cook, SM and Bromidge, FA and Newman, R and Smith, AJ and Wafford, KA and Marshall, GR and Reynolds, DS and Dias, R and Ferris, P and Stanley, J and Lincoln, R and Tye, SJ and Sheppard, WF and Sohal, B and Pike, A and Dominguez, M and Attack, JR and Castro, JL. (2006) Discovery of imidazo(1,2-b)(1,2,4)triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety J Med Chem, 49, pp. 1235-1238.
47. Schmitt, U and Hiemke, C. (1999) Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze Behav Pharmacol, 10, pp. 131-137.
48. Selak, I. (2001) Pregabalin (Pfizer) Curr Opin Invest Drugs, 2, pp. 828-834.
49. Sherif, F and Harro, J and El-Hwuegi, A and Oreland, L. (1994) Anxiolytic-like effect of the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA) on rat exploratory activity Pharmacol Biochem Behav, 49, pp. 801-805.
50. Strohle, A and Romeo, E and di Michele, F and Pasini, A and Hermann, B and Gajewsky, G and Holsboer, F and Rupprecht, R. (2003) Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results Arch Gen Psychiatry, 60, pp. 161-168.
51. Tauber, M and Calame-Droz, E and Prut, L and Rudolph, U and Crestani, F. (2003) Alpha2-gamma-aminobutyric acaid (GABA)A receptors are the molecular substrates mediating precipitation of narcosis but not of sedation by the combined use of diazepam and alcohol in vivo Eur J Neurosci, 18, pp. 2599-2604.
52. A receptors for the development of tolerance to the sedative action of diazepam in mice J Neurosci, 24, pp. 6785-6790.
53. Whiting, PJ. (2003) GABA-A receptor subtypes in the brain: A paradigm for CNS drug discovery? Drug Discov Today, 8, pp. 445-450.
54. Wieland, HA and Lüddens, H and Seeburg, PH. (1992) A single histidine in GABAA receptors is essential for benzodiazepine agonist binding J Biol Chem, 267, pp. 1426-1429.
55. Yee, BK and Hauser, J and Dolgov, VV and Keist, R and Mohler, H and Rudolph, U and Feldon, J. (2004) GABA receptors containing the alpha5 subunit mediate the trace effect in aversive and appetitive conditioning and extnction of conditioned fear Eur J Neurosci, 20, pp. 1928-1936.
56. Zwanzger, P and Baghai, T and Boerner, RJ and Möller, H-J and Rupprecht, R. (2001a) Anxiolytic effects of vigabatrin in panic disorder J Clin Psychopharmacol, 21, pp. 539-540.
57. Zwanzger, P and Baghai, TC and Schüle, C and Minov, C and Padberg, F and Möller, H-J and Rupprecht, R. (2001b) Tiagabine improves panic and agoraphobia in panic disorder patients J Clin Psychiatry, 62, pp. 656-657.
58. Zwanzger, P and Baghai, TC and Schüle, C and Strühle, A and Padberg, F and Kathmann, N and Schwarz, M and Möller, H-J and Rupprecht, R. (2001c) Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers Neuropsychopharmacology, 25, pp. 699-703.
59. Zwanzger, P and Eser, D and Padberg, F and Baghai, TC and Schüle, C and Rotzer, F and Ella, R and Möller, H-J and Rupprecht, R. (2003) Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers Depress Anxiety, 18, pp. 140-143.